, Dec. 14, 2010
/PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010
, at Pacifichem 2010 in Honolulu, Hawaii
. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns
, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
"We are very excited about the two structurally distinct clinical stage molecules, AM211 and AM461," said Peppi Prasit, Ph.D., Chief Scientific Officer. "In particular, the safety and pharmacodynamic readouts displayed by these compounds allowed us to investigate doses that ranged all the way to complete inhibition of the receptor at trough plasma concentrations."
The DP2 receptor is part of the Arachidonic Acid pathway and is also known as CRTH2, or chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes. DP2 is a high affinity receptor for the prostaglandin D2 and in humans is implicated in Th2-dependent allergic inflammation.
Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, fibrotic diseases and cancer. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. For more information, visit www.amirapharm.com.
SOURCE Amira Pharmaceuticals, Inc.